{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:09:04Z","timestamp":1785402544337,"version":"3.56.0"},"reference-count":22,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Aims\/Background: Tuberculosis (TB) is a highly prevalent opportunistic infection and a leading cause of mortality worldwide, particularly among those living with human immunodeficiency virus (HIV). Among these patients, the diagnostic accuracy of conventional TB testing is generally limited by atypical clinical manifestations, the frequent occurrence of extrapulmonary TB, challenges in obtaining sputum samples, and consistently low bacterial loads in clinical specimens. Therefore, this study assesses the diagnostic performance of a novel chemiluminescence immunoassay (CLIA) for detecting urinary lipoarabinomannan (LAM) in individuals coinfected with HIV and TB. Methods: A prospective cohort study was conducted involving 297 people living with HIV (PLWH) recruited from Beijing Youan Hospital, Capital Medical University, China, between May 2021 and December 2024. By September 2025, when this analysis was finalized, all patients had received at least 6 months of follow-up. Of these, 76 patients had TB (34 definite cases and 42 probable cases), while 221 non-TB patients with confirmed alternative diagnoses were included as a control group. A novel double-antibody sandwich CLIA was specifically designed to detect the Mycobacterium tuberculosis LAM antigen in urine specimens. For comparative evaluation, all samples were concurrently analyzed using the commercially available Determine\u2122 TB LAM Ag test (AlereLAM, Abbott Laboratories, USA). Investigators were blinded to the laboratory test results until the completion of enrollment, and laboratory technicians were blinded to patients\u2019 diagnoses throughout the study duration. Results: Receiver operating characteristic (ROC) analysis showed an area under the curve (AUC) of 0.925 at the optimal cutoff of 1.46. Median CLIA values increased in a graded manner across groups: 0.98 in the non-TB group, 1.96 in the probable TB group, and 4.46 in the definite-TB group (p &lt; 0.001). Compared with AlereLAM, CLIA demonstrated significantly higher sensitivity (85.3% vs. 58.8%) but lower specificity (89.6% vs. 98.2%). Neither LAM-CLIA nor AlereLAM exhibited a significant association with patient cluster of differentiation (CD) 4+ T cell counts (p &gt; 0.05). Conclusion: CLIA-based urinary LAM detection demonstrates superior sensitivity compared with conventional lateral flow assays, providing a rapid and quantitative approach for detecting HIV-associated TB. This method has significant potential to improve early TB detection in high-risk populations, particularly where culture-based methods are unavailable.<\/jats:p>","DOI":"10.31083\/bjhm56189","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:59:43Z","timestamp":1785398383000},"source":"Crossref","is-referenced-by-count":0,"title":["A Novel Chemiluminescent Immunoassay for Urinary LAM Detection Improves Tuberculosis Diagnosis in HIV Cohorts"],"prefix":"10.31083","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7960-6845","authenticated-orcid":true,"given":"Yu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Youan Hospital, Capital Medical University, 100069 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Youan Hospital, Capital Medical University, 100069 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Youan Hospital, Capital Medical University, 100069 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Youan Hospital, Capital Medical University, 100069 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5066-9827","authenticated-orcid":true,"given":"Yanhua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Youan Hospital, Capital Medical University, 100069 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, 100020 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Global Tuberculosis Report 2024. 2024. Available at: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024 (Accessed: 3 March 2025)."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Sossen B, Sz\u00e9kely R, Mukoka M, Muyoyeta M, Nakabugo E, Hella J, et al. Urine-Xpert Ultra for the diagnosis of tuberculosis in people living with HIV: a prospective, multicentre, diagnostic accuracy study. The Lancet. Global Health. 2024; 12: e2024\u2013e2034.","DOI":"10.1016\/S2214-109X(24)00357-7"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Tjale MA, Ombinda-Lemboumba S, Maphanga C, Mthunzi-Kufa P. TB diagnostic insights, progress made on point of care diagnostics and bioinformatics as an additional tool for improvement. The Indian Journal of Tuberculosis. 2023; 70: 468\u2013474.","DOI":"10.1016\/j.ijtb.2023.03.023"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"De K, Belardinelli JM, Pandurangan AP, Ehianeta T, Lian E, Pal\u010dekov\u00e1 Z, et al. Lipoarabinomannan modification as a source of phenotypic heterogeneity in host-adapted Mycobacterium abscessus isolates. Proceedings of the National Academy of Sciences of the United States of America. 2024; 121: e2403206121.","DOI":"10.1073\/pnas.2403206121"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Broger T, Koeppel L, Huerga H, Miller P, Gupta-Wright A, Blanc FX, et al. Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data. The Lancet. Global Health. 2023; 11: e903\u2013e916.","DOI":"10.1016\/S2214-109X(23)00135-3"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Correia-Neves M, Fr\u00f6berg G, Korshun L, Viegas S, Vaz P, Ramanlal N, et al. Biomarkers for tuberculosis: the case for lipoarabinomannan. ERJ Open Research. 2019; 5: 00115\u20132018.","DOI":"10.1183\/23120541.00115-2018"},{"key":"ref7","unstructured":"World Health Organization. Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV. 2019. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/0868522c-7bbf-4937-a553-11ec72be09e1\/content (Accessed: 10 November 2025)."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bonnet M, Gabillard D, Domoua S, Muzoora C, Messou E, Sovannarith S, et al. High Performance of Systematic Combined Urine Liboarabinomannan Test and Sputum Xpert MTB\/RIF for Tuberculosis Screening in Severely Immunosuppressed Ambulatory Adults With Human Immunodeficiency Virus. Clinical Infectious Diseases. 2023; 77: 112\u2013119.","DOI":"10.1093\/cid\/ciad125"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mangu C, Cossa M, Ndege R, Khosa C, Leukes V, de la Torre-P\u00e9rez L, et al. Expanding Xpert MTB\/RIF Ultra\u00ae and LF-LAM testing for diagnosis of tuberculosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: a randomized controlled trial (the EXULTANT trial). BMC Infectious Diseases. 2024; 24: 831.","DOI":"10.1186\/s12879-024-09651-z"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Huerga H, Mathabire Rucker SC, Cossa L, Bastard M, Amoros I, Manhi\u00e7a I, et al. Diagnostic value of the urine lipoarabinomannan assay in HIV-positive, ambulatory patients with CD4 below 200 cells\/\u00b5l in 2 low-resource settings: A prospective observational study. PLoS Medicine. 2019; 16: e1002792.","DOI":"10.1371\/journal.pmed.1002792"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Li H, Gao X, Liu D, Li Z, Li J. A new strategy improving TB diagnosis: stratified urine LAM test based on lymphocyte counts. Frontiers in Cellular and Infection Microbiology. 2025; 15: 1498651.","DOI":"10.3389\/fcimb.2025.1498651"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition). Chinese Medical Journal. 2024; 137: 2654\u20132680.","DOI":"10.1097\/CM9.0000000000003383"},{"key":"ref13","unstructured":"National Health and Family Planning Commission of the People\u2019s Republic of China. Diagnosis for pulmonary tuberculosis. 2017. Available at: https:\/\/www.nhc.gov.cn\/ewebeditor\/uploadfile\/2017\/11\/20171128164254246.pdf (Accessed: 3 March 2025). (In Chinese)"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Flores J, Cancino JC, Chavez-Galan L. Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis: How Far Are We to Use It? Frontiers in Microbiology. 2021; 12: 638047.","DOI":"10.3389\/fmicb.2021.638047"},{"key":"ref15","unstructured":"World Health Organization. WHO standard: universal access to rapid tuberculosis diagnostics. 2023. Available at: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/4d4114e9-c439-4f03-ad4a-cf12e07304a0\/content (Accessed: 10 November 2025)."},{"key":"ref16","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. 2025. Available at: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/b9125fa4-dcc0-418a-9421-56c28275461d\/content (Accessed: 10 November 2025)."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Chatla C, Mishra N, Jojula M, Adepu R, Puttala M. A systematic review of utility of urine lipoarabinomannan in detecting tuberculosis among HIV-positive tuberculosis suspects. Lung India. 2021; 38: 64\u201373.","DOI":"10.4103\/lungindia.lungindia_574_19"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Broger T, Nicol MP, Sigal GB, Gotuzzo E, Zimmer AJ, Surtie S, et al. Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. The Journal of Clinical Investigation. 2020; 130: 5756\u20135764.","DOI":"10.1172\/JCI140461"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, et al. A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO\u2019s Performance Target for Tuberculosis Diagnosis. Journal of Clinical Microbiology. 2018; 56: e01338-18.","DOI":"10.1128\/JCM.01338-18"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Huang L, Niu Y, Zhang L, Yang R, Wu M. Diagnostic value of chemiluminescence for urinary lipoarabinomannan antigen assay in active tuberculosis: insights from a retrospective study. Frontiers in Cellular and Infection Microbiology. 2023; 13: 1291974.","DOI":"10.3389\/fcimb.2023.1291974"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Liu R, Li J, Tan Y, Shang Y, Li Y, Su B, et al. Multicenter evaluation of the acid-fast bacillus smear, mycobacterial culture, Xpert MTB\/RIF assay, and adenosine deaminase for the diagnosis of tuberculous peritonitis in China. International Journal of Infectious Diseases. 2020; 90: 119\u2013124.","DOI":"10.1016\/j.ijid.2019.10.036"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Benjamin A, Cavalcante SC, Jamal LF, Arakaki-Sanchez D, de Lima JN, Pilotto JH, et al. Accuracy of Determine TB-LAM Ag to detect TB in HIV infected patients associated with diagnostic methods used in Brazilian public health units. PLoS ONE. 2019; 14: e0221038.","DOI":"10.1371\/journal.pone.0221038"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/7\/10.31083\/BJHM56189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:00:12Z","timestamp":1785398412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/7\/10.31083\/BJHM56189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)03315-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm56189","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"56189"}}